Abstract
The term “neoadjuvant chemotherapy” was first described by Frei in his Karnofsky lecture, where it was used to describe the use and benefits of preoperative chemotherapy for the treatment of malignant tumors (Frei 1982). An early example of the use of neoadjuvant or preoperative chemotherapy was in the development of effective treatment for osteogenic sarcoma, the most common malignant bone tumor seen in the adolescent and young adult population (Rosen et al. 1982). The advantages of neoadjuvant chemotherapy on theoretical grounds would appear to be the early elimination of metastatic microfoci of disease that exist in the majority of patients harboring fully malignant (ostensibly only) primary malignant tumors. Early aggressive therapy theoretically would not only destroy metastatic microfoci of disease that exists systemically, but by the use of aggressive chemotherapy that can cause regression of the primary tumor, presumably the emergence of resistant tumor cells would be prevented.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Carter SK (1984) Adjuvant chemotherapy in osteogenic sarcoma: The triumph that isn’t? J Clin Oncol 2(3): 147–148
Cortes EP, Holland JF, Wang JJ, Glidewell O (1975) Adriamycin (NSC-123127), in 87 patients with osteogenic sarcoma. Cancer Chemother Rep 6: 305–313
Cortes EP, Necheles TF, Holland JF, et al (1979) Adriamycin (ADR) alone vs ADR and high-dose methotrexate-citrovorum factor rescue (HDM-CFR) ad adjuvant to operable primary osteosarcoma. A randomized study by Cancer and Leukemia Group B (CALGB). Proc Am Assoc Cancer Res 20: 412
Edmonson JH, Green SJ, Ivins JC, et al (1984) A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma. J Clin Oncol 2(3): 152–156
Ettinger LJ, Douglass HO, Highby DJ, et al. (1981) Adjuvant adriamycin (Adr) and cis-diammine-dichloroplatinum (cis-platinum) in primary costesarcoma. Cancer 47: 248–254
Frei E (1982) Clinical cancer research: an embattled species. Cancer 50: 1979–1992
Jaffe N, Frei E, Watts H, et al (1978) High-dose methotrexate in osteogenic sarcoma. A 5-year experience. Cancer Treat Rep 62: 259–264
Kalifa C, Dubousset J, Contesso G, Vandel D, Lumbroso J, Lemerle J (1985) Osteosarcoma: an attempt to reproduce T-10 protocol in a single institution. Proc Am Soc Clin Onc 4: 236 (Abstr 919)
Link MP (1984) The role of adjuvant chemotherapy in the treatment of osteosarcoma of the extremity: preliminary results of the multi-institutional osteosarcoma study. Proceedings of National Institutes of Health Consensus Development Conference on Limb-sparing treatment: adult soft-tissue and osteogenic sarcomas. December 3–5, 1984, pp 74–78
Mosende C, Guittierez M, Caparros B, Rosen G (1977) Combination chemotherapy with bleomycin, cyclophosphamide and dactinomycin for the treatment of osteogenic sarcoma. Cancer 40: 2779–2786
Nirenberg A, Mosende C, Mehta BM, Gisolfi AL, Rosen G (1977) High dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity. Cancer Treat Rep 61: 779–783
Pratt CB, Shanks EC, Hustu HO, et al (1977) Adjuvant multiple drug chemotherapy for esteogenic sarcoma of the extremity. Cancer 39: 51–57
Reiman RE, Rosen G, Gelbard AS, Benua, RS, Laughlin JS (1982) Imaging of primary Ewing sarcoma with 13N-l-glutamate. Radiology 42(2): 495–500
Rosen G (1985) Chemotherapy for osteogenic sarcoma. In: Brian MC, Carbone PP (eds) Current therapy in hematology-oncology. Mosby, St. Louis, pp 217–224
Rosen G, Nirenberg A (1982) Chemotherapy for osteogenic sarcoma: an investigative method, not a recipe. Cancer Treat Rep 55: 1687–1697
Rosen G, Murphy ML, Huvos AG, et al (1976) Chemotherapy, en bloc resection and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer 37: 1–11
Rosen G, Marcove RC, Caparros B, et al (1979) Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery. Cancer 43: 2163–2177
Rosen G, Nirenberg A, Caparros B, et al (1980) Cis-platinum in metastatic osteogenic sarcoma. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin: current status and new developments. Academic, New York pp 465–475
Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcova RC, Lane JM, Mehta B, Urban C (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49: 1221–1230
Yeh SD, Rosen G, Caparros B, Benua RS (1984) Semiquantitative gallium scintigraphy in patients with osteogenic sarcoma. Clin Nucl Med 9: 175–183
Winkler K, Beron G, Kotz R, et al. (1984) Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian Study. J Clin Oncol 2(6): 617–623
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Rosen, G. (1986). Neoadjuvant Chemotherapy for Osteogenic Sarcoma: A Model for the Treatment of Other Highly Malignant Neoplasms. In: Ragaz, J., Band, P.R., Goldie, J.H. (eds) Preoperative (Neoadjuvant) Chemotherapy. Recent Results in Cancer Research, vol 103. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-82671-9_17
Download citation
DOI: https://doi.org/10.1007/978-3-642-82671-9_17
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-82673-3
Online ISBN: 978-3-642-82671-9
eBook Packages: Springer Book Archive